FDA let artificial-blood trials continue despite risks
Wednesday, April 30, 2008 - 13:51
in Health & Medicine
A report that pools data from 16 studies concludes that the FDA should have halted research years earlier because of increased incidence of heart attacks and deaths. Despite evidence that a group of experimental blood substitutes nearly tripled the risk of heart attacks and caused a 30% increase in deaths, the Food and Drug Administration continued to approve some clinical trials of the products, researchers said Monday.
Read the whole article
See latest science articles from LA Times - Science
Latest Science Newsletter
Get the latest and most popular science news articles of the week in your Inbox!Related
- ACCORD clinical trial publishes resultsFri, 6 Jun 2008, 17:35:45 EDT
- Common COPD medications linked with increased risk of CV death, heart attackTue, 23 Sep 2008, 16:43:40 EDT
- Risk of sudden cardiac death appears increased within 30 days of heart attackTue, 4 Nov 2008, 16:36:13 EST
- When statins aren't enough: New trial drug points to better management of coronary heart diseaseThu, 8 May 2008, 14:22:20 EDT
- Blood pressure drug combination reduces heart attack deathsTue, 16 Sep 2008, 13:45:51 EDT